Christopher OBrien - Neurocrine Biosciences Chief Medical Officer
| NBIX Stock | USD 136.91 0.92 0.68% |
Executive
Dr. Christopher F. OBrien, M.D., is no longer Chief Medical Officer of Neurocrine Biosciences, Inc. effective on February 2018. He became Chief Medical Officer in January 2007 after having served as Senior Vice President of Clinical Development since 2005. He is responsible for clinical operations, regulatory affairs, drug safety, biostatistics and data management. Prior to joining Neurocrine, he was Chief Medical Officer at Prestwick Pharmaceuticals, Inc. from 2003 to 2005 and Senior Vice President of Global Medical Affairs at Elan Pharmaceuticals, Inc. from 2000 to 2003. Dr. OBrien is currently on the Board of Directors of Verifax Corporationrationration, a biometrics company focused on developing a dynamic signature verification system. Dr. OBrien is a BoardCertified Neurologist and obtained his undergraduate degree in Neuroscience from Boston University, his medical degree and residency training from the University of Minnesota and fellowship training from the University of Rochester School of Medicine. since 2007.
| Age | 59 |
| Tenure | 17 years |
| Address | 12780 El Camino Real, San Diego, CA, United States, 92130 |
| Phone | 858 617 7600 |
| Web | https://www.neurocrine.com |
Neurocrine Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.0878 % which means that it generated a profit of $0.0878 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1268 %, meaning that it created $0.1268 on every $100 dollars invested by stockholders. Neurocrine Biosciences' management efficiency ratios could be used to measure how well Neurocrine Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.08 in 2024. Return On Capital Employed is likely to rise to 0.10 in 2024. At this time, Neurocrine Biosciences' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Morgan Flatley | McDonalds | 49 | |
| Sheri Bronstein | Bank of America | 51 | |
| Diana Sroka | HP Inc | N/A | |
| Vittorio Cretella | Procter Gamble | N/A | |
| Jamie Engstrom | Caterpillar | N/A | |
| David Rozzion | HP Inc | N/A | |
| Ruairidh Ross | HP Inc | N/A | |
| Bryan Hanson | 3M Company | 57 | |
| Michael Guptan | Walmart | N/A | |
| Mark II | 3M Company | 56 | |
| Mary Francis | Chevron Corp | 60 | |
| Allyson Park | Walmart | N/A | |
| Carrie Palin | Cisco Systems | 52 | |
| Luigi Faltoni | 3M Company | N/A | |
| Gillian McDonald | McDonalds | 58 | |
| Matthew Miner | Walmart | N/A | |
| Deborah Majoras | Procter Gamble | 57 | |
| Victoria Wong | Cisco Systems | 57 | |
| Damon Jones | Procter Gamble | 48 | |
| Brian Rice | McDonalds | 61 | |
| Suzette Long | Caterpillar | 58 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 |
Neurocrine Biosciences Leadership Team
Elected by the shareholders, the Neurocrine Biosciences' board of directors comprises two types of representatives: Neurocrine Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neurocrine. The board's role is to monitor Neurocrine Biosciences' management team and ensure that shareholders' interests are well served. Neurocrine Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neurocrine Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Mollica, Independent Director | ||
| George Morrow, Director | ||
| Matthew Abernethy, Chief Officer | ||
| Richard Pops, Independent Director | ||
| Eric Benevich, Chief Commercial Officer | ||
| William Rastetter, Independent Chairman of the Board | ||
| Darin Lippoldt, Chief Legal Officer | ||
| Alfred Sandrock, Director | ||
| Jude Onyia, Chief Officer | ||
| Matt Abernethy, CFO | ||
| Navjot Rai, IR Contact Officer | ||
| Darin Esq, Chief Secretary | ||
| Bill Aurora, Vice President - Medical Affairs | ||
| David Boyer, Chief Officer | ||
| Christopher OBrien, Chief Medical Officer | ||
| Stephen Sherwin, Independent Director | ||
| Julie Cooke, Chief People Officer | ||
| DavidAlexandre Gros, President COO | ||
| Eiry Roberts, Chief Medical Officer | ||
| Corinne Nevinny, Independent Director | ||
| Dimitri Grigoriadis, Chief Research Officer | ||
| Haig Bozigian, Chief Devel. Officer | ||
| Kyle Gano, Chief Business Development Officer | ||
| Gary Lyons, Independent Director | ||
| Timothy Coughlin, CFO, Principal Accounting Officer and VP | ||
| Jane Sorensen, Investor Relations Officer | ||
| Malcolm LloydSmith, Chief Regulatory Officer | ||
| Eiry MD, Chief Officer | ||
| Kevin Gorman, CEO and President and Director | ||
| Ingrid Delaet, Chief Officer |
Neurocrine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neurocrine Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0878 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 12.96 B | ||||
| Shares Outstanding | 100.58 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 94.71 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | 202.90 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Complementary Tools for Neurocrine Stock analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.648 | Earnings Share 2.48 | Revenue Per Share 19.315 | Quarterly Revenue Growth 0.25 | Return On Assets 0.0878 |
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.